Aurinia Pharmaceuticals (AUPH) Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. SPY
9. EVMN
10. AAPL

Go back to Aurinia Pharmaceuticals (AUPH) Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
(NASDAQ: AUPH) Delayed: 16.13 +0.06 (0.37%)
Previous Close $16.07    52 Week High $5.69 
Open $15.97    52 Week Low $1.42 
Day High $16.29    P/E N/A 
Day Low $15.85    EPS $0.00 
Volume 206,300